Articles tagged with Breast Cancer
Research suggests that radiation therapy is not necessary for older women with low risk of breast cancer recurrence, according to a recent editorial published in the Journal of Clinical Oncology. The study found that patients over 70 years old with estrogen receptor-positive tumors did not show improved survival or quality of life with...
A new survey conducted by the American Society of Plastic Surgeons found that 89% of women want to see the results of breast reconstruction surgery before undergoing treatment for breast cancer. The ASPS is launching a campaign to educate women about their options and provide a platform for patients to share their experiences.
Researchers at Ohio State University discovered that combining two peptide agents with a low-dose chemotherapy drug can delay tumor onset and progression in breast cancer models. The treatments caused few side effects.
Researchers have validated a radiosensitivity molecular signature that can predict clinical outcomes in patients treated with radiation therapy for breast cancer. The technology, called RSI, identifies radiosensitivity and radioresistance, opening the door to biologically guided radiation therapy.
Professors Ian Tannock and Jean Yves Blay will receive the 2012 ESMO Awards for their contributions to medical oncology. The European Organisation for Research and Treatment of Cancer (EORTC) is recognized with the ESMO Lifetime Achievement Award.
Researchers found that pre-test genetic counseling decreases distress in before-surgery patients, while improving informed decision-making in after-surgery patients. Both groups showed increased cancer knowledge following the counseling.
Infants born to mothers who received chemotherapy during pregnancy had lower birth weights but no higher risk of birth defects or blood disorders. The study suggests that breast cancer treatment during pregnancy is possible and prioritizing full-term delivery may be crucial for minimizing risks.
A phase III study published in Clinical Cancer Research found that denosumab reduced skeletal-related events by 31% compared to zoledronic acid, while also maintaining health-related quality of life. Treatment with denosumab also showed fewer acute reactions and adverse events.
A new study published in Cancer found that radiation after lumpectomy significantly reduced the risk of needing a mastectomy in older women with early-stage breast cancer. Radiation was shown to be beneficial for patients with high-grade tumors, while those with non-high grade tumors did not derive as much benefit.
Researchers at Case Western Reserve University have identified a new oncogene, FAM83B, which contributes to the development of breast cancer. Elevated expression of this gene is associated with the more aggressive triple-negative subgroup, highlighting the need for new therapeutic options.
Scientists at Sanford-Burnham Medical Research Institute found a molecule that promotes tumor vessel maturation, which could improve the effectiveness of anti-cancer therapies. By boosting R-Ras activity, researchers aim to normalize blood vessel structure and function in tumors, enabling better drug delivery.
A recent study found that radiation therapy after lumpectomy can help prevent mastectomy in early-stage breast cancer patients, particularly those with high-grade tumors. The research, published in the Journal Cancer, contradicts current national treatment guidelines.
A new method of delivering trastuzumab via subcutaneous injection has been found to be as effective as traditional intravenous delivery, with similar pathologic complete response rates. This could simplify breast cancer treatment, saving time for patients and reducing hospital dependence.
A study by Lawson Research Institute suggests that breast cancer stem cells have a preference for specific organs, such as the lung and brain, when spreading to other sites. Researchers hope to uncover the underlying factors driving this phenomenon and potentially develop new strategies to target these aggressive cells.
A new sequencing approach using long-range PCR and Next Generation Sequencing has been developed to provide a more effective method of BRCA1/2 mutational analysis. The method was successfully tested on 12 familial breast cancer patients, identifying all expected variants with high accuracy.
New human-derived breast cancer models retain heterogeneity, allowing researchers to test drugs more accurately. These models can help identify unique features in individual tumors, enabling targeted treatment.
A study published in the Journal of the National Cancer Institute found that a plant-based compound called phenethyl isothiocyanate (PEITC) slowed breast cancer growth in mice. PEITC was shown to reduce mammary carcinoma lesions by 56.3% and suppress tumor progression.
Researchers found that HSF1 activates a transcriptional program distinct from heat shock, driving the development of aggressive cancer phenotypes in breast, lung, and colon cancers. The findings suggest HSF1 as a potential therapeutic target for treating multiple cancer types.
A recent study in Pakistan found limited awareness of breast cancer among most women, with many unaware of self-breast exams and clinical breast exams. However, willingness to address health issues was high, and the majority of general practitioners understood major risk factors and importance of early detection.
Spouses of breast cancer patients struggle to find hope and balance in their lives, with many turning to exercise, music, and hobbies to cope. The study suggests that men need specific support and resources tailored to their needs, such as online guides and practical advice, to help manage stress and improve quality of life.
A combination of anastrozole and fulvestrant extended the median survival time of women with Stage 4 hormone receptor-positive metastatic breast cancer. The treatment option showed a significant overall survival benefit, particularly exciting for patients who have not had a new treatment in over a decade.
The combination of anastrozole and fulvestrant improved overall survival and progression-free survival in postmenopausal women with hormone receptor-positive metastatic breast cancer. The study showed a six-month extended median survival time compared to anastrozole alone, and improved median time to disease progression.
A study published in the New England Journal of Medicine found that combining two drugs extended the lives of women with metastatic breast cancer by more than six months. The combination treatment produced even greater benefits among women who had not previously taken tamoxifen, significantly improving survival rates.
Scientists at Western University have identified Nodal as a promising new therapeutic target for advanced breast cancer. The protein promotes vascularization, providing nutrients and oxygen to tumors, and its expression is correlated with more blood vessels in the tumor.
A team of researchers used computational analysis to identify a new therapeutic strategy for treating drug-resistant breast cancer. The study found that disrupting glucose metabolism is an effective approach, targeting existing drugs like Lapatinib. This discovery may offer improved treatments for breast cancer patients.
Researchers at A*STAR's Institute of Molecular and Cell Biology have devised a fast and cost-saving way to uncover genetic changes associated with cancer. By studying fruit flies, they identified new 'cooperating' genes that work together to cause aggressive cancer.
Researchers found that breast cancer patients lacking the retinoblastoma tumor suppressor gene (RB) had a better pathological response to neoadjuvant chemotherapy. A prospective clinical trial has been initiated at the Kimmel Cancer Center to explore this finding further.
A study by University of Michigan researchers found that an inflammatory pathway involving Interleukin-6 drives resistance to Herceptin in HER2-positive breast cancers. Blocking this pathway with a drug improved the treatment's effectiveness, and also prevented cancer stem cells from forming.
A recent study from the University of Texas Medical Branch at Galveston found that delivering a high-birth-weight infant more than doubles a woman's breast cancer risk. The researchers suggest that this increased risk is due to an elevated hormonal environment during pregnancy, which creates a pro-carcinogenic effect.
A study published in the Journal of the National Cancer Institute found that breast cancer mortality rates in Swedish women aged 40-69 declined at a rate similar to the prescreening period, suggesting limited impact of mammography screening. Researchers note potential limitations, including obesity and population mobility biases.
Physiologists and neuropathologists from the University of Zurich have identified the origin of metastasis formation in intestinal cancer cells. Cancer cells manipulate specific doorman receptors on blood vessel endothelium to enter other organs via bloodstream.
Researchers at Brigham and Women's Hospital have developed a new approach to cancer treatment using supramolecular nanochemistry. The innovative nanoparticles significantly enhanced antitumor activity while reducing toxicity in breast and ovarian cancer models.
A study found that women using fertility drugs had a reduced risk of breast cancer if they did not conceive a 10-plus week pregnancy, but an increased risk if they did. The study suggests that exposure to the drugs may raise risk by modifying breast tissue remodeling during pregnancy.
The Center for Cancer Support and Education in Arlington, Mass., will receive a $10,000 grant from ASTRO's Survivor Circle program to fund breast cancer, advanced cancer, and brain cancer support groups. The Center offers emotional support during treatment and recovery for patients and their family members.
A study by 23andMe identified seven single-nucleotide polymorphisms (SNPs) associated with breast size, including three linked to breast cancer. The analysis controlled for age, ancestry, and other factors, providing insight into the genetic factors underlying normal breast development.
A new study presents the largest number of preimplantation genetic diagnosis (PGD) treatments for BRCA1/2 in Europe, with a significant proportion of successful pregnancies. The results suggest that PGD offers an established option for couples seeking to avoid inherited BRCA mutations.
A BUSM in vitro study discovered a potent combination therapy for breast cancer, including triple-negative and hormone-refractory cases. The treatment re-expressed imprinted tumor suppressor genes, inhibiting cancer cell growth and promoting death.
A study published in The Journal of Nuclear Medicine found that imaging progesterone receptor (PR) status can identify responders and nonresponders to endocrine therapy in early stages. PR imaging with F-18-FFNP PET may help distinguish between patients who will benefit from hormone-based therapies.
Researchers at Georgetown University Medical Center discovered that glucose-regulated protein 78 (GRP78) is a major determinant of resistance to anti-estrogen therapy. Inhibiting GRP78 may provide a solution for tens of thousands of women who develop resistance to these drugs.
Researchers have developed a simple and cost-effective imaging device for breast tumor detection using a flexible wearable antenna system. The system shows promise of detecting breast cancer earlier than other methods by analyzing microwave signals from skin contact, reducing signal loss compared to traditional designs.
Preventive mammography rates in women aged 40-49 have dropped nearly 6 percent nationwide since the USPSTF recommended against routine mammograms. The decline is consistent with public resistance to the guidelines change and a modest effect seen in the first year after publication.
Georgetown University Medical Center will establish the Center of Excellence for Health Disparities, focusing on eliminating health disparities among minority populations in Washington, D.C. The center aims to reduce chronic diseases such as breast cancer and stroke through research, education, and community engagement.
Research finds that physical activity, regardless of intensity, may reduce breast cancer risk in women. Exercise before or after menopause can lower the risk, especially for hormone receptor-positive tumors.
A new analysis found that physical activity may reduce breast cancer risk by 30% in women, with moderate activity providing the greatest benefit. Exercise before or after menopause also shows promise in reducing breast cancer risk, particularly for hormone receptor-positive tumors.
The study discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles released by tumor cells may provide a unique biosignature for individual cancers, enabling early detection and targeted therapies.
Researchers have discovered a new method to sub-typing GBM tumor lines using proteins expressed, which could lead to targeted drug treatments and more accurate patient prognoses. The study found that patients with the CNP subtype may live up to 10 years after diagnosis.
Researchers uncovered surprises in genes previously thought uninvolved in breast cancer, revealing the complex drivers of this leading cause of cancer death. The study found novel fusion gene MAGI1-AKT3, which acts as an oncogene and offers new therapy targets.
Researchers have discovered a new indicator for breast cancer relapse, directly associated with the activation of NF-kB signaling in tumour cells. The absence of the 14-3-3 protein sigma is not itself a prognosis factor, but its lack enables chronic NF-kB activity linked to tumour progression.
A major population study found that women who worked nights had a 30% higher risk of developing breast cancer compared to those who never worked nights. The study also suggested that women who worked at night prior to a first pregnancy may be more vulnerable to the increased risk.
Researchers identified significant variation in microRNA expression within single tumors, highlighting the importance of sampling multiple tumor zones. This finding may explain conflicting previous results and emphasizes the need for personalized medicine approaches.
The Damon Runyon Cancer Research Foundation awarded $3.3 million to eight promising young clinical investigators, focusing on breast cancer and brain tumors.
A preclinical study found that normal p53, a tumor suppressor gene, makes breast cancer chemotherapy with doxorubicin less effective. Senescent cells produced by non-mutated p53 fueled the relapse of tumors. The research challenges the existing paradigm and is another step closer to personalized cancer medicine.
A study suggests that women can reduce their breast cancer risk by avoiding unnecessary medical imaging. According to the UCSF analysis of IOM report, radiation exposure from medical imaging is a known risk factor for breast cancer.
Dr. Rowan Chlebowski, a leading breast cancer researcher at LA BioMed, has been recognized for his significant contributions to cancer prevention and control through the ASCO-American Cancer Society Award and Lecture. His work on clinical trials and lifestyle interventions has reduced breast cancer recurrence and incidence.
A Vanderbilt-led study identified a gene expression pattern linked to resistance to breast cancer chemotherapy. The researchers found that tumors with low concentrations of the dual specificity protein phosphatase 4 (DUSP4) were more resistant to chemotherapy, suggesting new therapy options for patients with specific subtypes of breast...
Researchers identified distinct cancer signatures linked to treatment response in breast tumors, which could help personalize treatment for patients. The study found mutations in genes like TP53 and MAP3K1 associated with good response to aromatase inhibitors, while others like MALAT1 predicted poor outcomes.
A new blood test discovered circulating tumour cells can predict progression-free survival and overall survival in early-stage breast cancer patients. The presence of CTCs is associated with worse survival rates, but the correlation increases when concentrations are higher.
A study found that women treated with chest radiation for childhood cancer have a high risk of developing breast cancer comparable to those with BRCA1/2 mutations. The study analyzed data from over 1,200 female survivors and found a 24% breast cancer incidence by age 50.
Researchers have identified changes in adult stem cells and tumor suppressors that contribute to age-related breast cancer vulnerability. The 'HMEC Aging Resource' provides a valuable resource for studying cellular aging, allowing researchers to explore potential preventative measures.
A Mayo Clinic-led study found that high doses of American ginseng reduced cancer-related fatigue in patients more effectively than a placebo. The herb showed significant improvement in general exhaustion at eight weeks, with no apparent side effects.